Manzotti M, Dell'Orto P, Maisonneuve P, Zurrida S, Mazzarol G, Viale G
Department of Pathology, European Institute of Oncology, Via Ripmaonti 435, I-20141 Milan, Italy.
Int J Cancer. 2001 Sep 20;95(5):307-12. doi: 10.1002/1097-0215(20010920)95:5<307::aid-ijc0153>3.0.co;2-q.
The identification of specific tumor mRNA markers by reverse transcription-polymerase chain reaction might be a valuable diagnostic adjunct for the detection of breast cancer metastases in axillary sentinel lymph nodes (SLNs). In this study we have compared the diagnostic accuracy of an extensive histopathologic examination of 146 SLNs from 123 breast carcinoma patients with that of the evaluation of 5 mRNA markers. When analyzed individually, none of the different markers attained a sensitivity higher than 77.8%, and the general concordance with the histopathologic findings ranged from 78.8 to 83.6%. In a multiple-marker assay, taking into account the expression of at least 1 of the 5 tumor markers, the sensitivity of the test rose to 95.6%, with a specificity of 66.3% and a general concordance with the histopathologic status of 75.3%. Finally, when at least 2 of 3 markers (maspin, cytokeratin 19 and mammaglobin 1) were expressed, the concordance with either SLN or axillary lymph node status was highest (88.4% and 84.6%, respectively). The high prevalence of positive reverse transcription-polymerase chain reaction assays in histologically uninvolved SLNs, however, may hamper extensive application of these techniques in the clinical setting.
通过逆转录 - 聚合酶链反应鉴定特定肿瘤mRNA标志物可能是检测腋窝前哨淋巴结(SLN)中乳腺癌转移的一种有价值的诊断辅助手段。在本研究中,我们比较了123例乳腺癌患者的146个SLN的广泛组织病理学检查与5种mRNA标志物评估的诊断准确性。单独分析时,不同标志物的敏感性均未超过77.8%,与组织病理学结果的总体一致性在78.8%至83.6%之间。在多标志物检测中,考虑到5种肿瘤标志物中至少1种的表达情况,检测的敏感性升至95.6%,特异性为66.3%,与组织病理学状态的总体一致性为75.3%。最后,当3种标志物(组织蛋白酶抑制剂、细胞角蛋白19和乳腺珠蛋白1)中至少2种表达时,与SLN或腋窝淋巴结状态的一致性最高(分别为88.4%和84.6%)。然而,在组织学上未受累的SLN中逆转录 - 聚合酶链反应检测阳性的高发生率可能会阻碍这些技术在临床环境中的广泛应用。